Immunovaccine to Hold Webcast and Conference Call to Discuss Clinical Data From Its Collaborative Combination Immunotherapy T...
December 04 2017 - 4:05PM
Immunovaccine Inc. (TSX:IMV) (OTCQX:IMMVF), a clinical stage
immuno-oncology company, today announced that it will hold a
webcast and conference call tomorrow (Tuesday, December 5, 2017) at
8:00 a.m. ET.
The purpose of this conference call is to share top-line
clinical data from its ongoing Phase 1b trial evaluating the safety
and efficacy of Immunovaccine’s lead immuno-oncology candidate,
DPX-Survivac, in combination with Incyte’s IDO1 enzyme inhibitor
epacadostat, and low-dose cyclophosphamide in patients with
advanced ovarian cancer. Immunovaccine is conducting the trial in
collaboration with Incyte Corporation.
The webcast will be preceded by a press release announcing the
findings from the trial thus far.
Conference Call and Webcast InformationThe call
can be accessed by dialing (844) 461-9932 (U.S. and Canada) or
(636) 812-6632 (International) with the conference ID# 3558749. You
can access the live audio webcast and presentation via this link,
or by pasting this URL in your browser:
https://edge.media-server.com/m6/p/9u4kwnce.
About ImmunovaccineImmunovaccine Inc. is a
clinical stage biopharmaceutical company dedicated to making
immunotherapy more effective, more broadly applicable, and more
widely available to people facing cancer and other serious
diseases. Immunovaccine develops T cell-activating cancer
immunotherapies and other vaccine candidates based on DepoVax™, the
Company’s patented platform that provides controlled and prolonged
exposure of antigens and adjuvant to the immune system.
Immunovaccine has advanced two T cell-activating therapies for
cancer through Phase 1 human clinical trials and is currently
conducting a Phase 1b study with Incyte Corporation assessing lead
cancer therapy, DPX-Survivac, as a combination therapy in ovarian
cancer as well as two Phase 2 trials with Merck in ovarian cancer
and DLBCL. The Company is also exploring additional applications of
DepoVax, including DPX-RSV, an innovative vaccine candidate for
respiratory syncytial virus (RSV), which has recently completed a
Phase 1 clinical trial. Immunovaccine also has ongoing clinical
projects to assess the potential of DepoVax to address malaria and
the Zika virus. Connect at www.imvaccine.com.
Immunovaccine Forward-Looking StatementsThis
press release contains forward-looking information under applicable
securities law. All information that addresses activities or
developments that we expect to occur in the future is
forward-looking information. Forward-looking statements are based
on the estimates and opinions of management on the date the
statements are made. However, they should not be regarded as a
representation that any of the plans will be achieved. Actual
results may differ materially from those set forth in this press
release due to risks affecting the Company, including access to
capital, the successful completion of clinical trials and receipt
of all regulatory approvals. Immunovaccine Inc. assumes no
responsibility to update forward-looking statements in this press
release except as required by law.
Contacts for Immunovaccine:
MEDIA Mike Beyer, Sam Brown
Inc.T: (312) 961-2502 E: mikebeyer@sambrown.com
INVESTOR RELATIONSPierre Labbé, Chief
Financial OfficerT: (902) 492-1819 E:
info@imvaccine.com
Patti Bank, Managing Director, Westwicke
PartnersO: (415) 513-1284T: (415) 515-4572 E:
patti.bank@westwicke.com
IMV (TSX:IMV)
Historical Stock Chart
From Jun 2024 to Jul 2024
IMV (TSX:IMV)
Historical Stock Chart
From Jul 2023 to Jul 2024